Doctor and patient discussing chart

Cancer Center

Clinical Research Trials

Lake Region Healthcare’s Cancer Care and Research Center partners with the Essentia Institute of Rural Health in Duluth, MN to offer Clinical Research Trials. This partnership allows our patients the opportunity to participate in National Cancer Institute-sponsored clinical trials without having to leave our community.

Clinical trial participation is an option for cancer treatment and allows patients the opportunity to receive treatment or medications they may not otherwise have access to. Clinical trials help cancer specialists improve cancer treatment and side effect management.

These trials are approved by the Food and Drug Administration and the National Cancer Institute. They are also approved by the Institutional Review Board (IRB), an organization that assures the treatments are reasonable and safe.

If you have questions regarding our clinical research trial program, please contact our Clinical Research Nurse at 218.736.8636

Current Clinical Trials

Click on a trial below to see trial details.

Breast

A011401

Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Specialty: Cancer, Oncology & Hematology
Description: This randomized phase III trial studies whether weight loss in overweight and obese women may prevent breast cancer from coming back (recurrence). Previous studies have found that women who are overweight or obese when their breast cancer is found (diagnosed) have a greater risk of their breast cancer recurring, as compared to women who were thinner when their cancer was diagnosed. This study aims to test whether overweight or obese women who take part in a weight loss program after being diagnosed with breast cancer have a lower rate of cancer recurrence as compared to women who do not take part in the weight loss program. This study will help to show whether weight loss programs should be a part of breast cancer treatment. https://clinicaltrials.gov/ct2/show/NCT02750826?term=A011401&rank=1
More information: For more information on this clinical trial offering at Lake Region Healthcare Cancer Care & Research Center, please contact our Clinical Research Nurse at 218.736.8636.

E2112

ECOG 2112: A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer
Specialty: Cancer, Oncology & Hematology
Description: This randomized phase III trial studies exemestane and entinostat to see how well they work compared to exemestane alone in treating postmenopausal patients with hormone receptor-positive breast cancer that has spread to nearby tissue or lymph nodes or another place in the body. Estrogen can cause the growth of breast cancer cells. Endocrine therapy using exemestane may fight breast cancer by lowering the amount of estrogen the body makes. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether exemestane is more effective with or without entinostat in treating breast cancer. cancer.gov/clinicaltrials/search/view?cdrid=760055&version=HealthProfessional&protocolsearchid=13427099
More Information: For more information on this clinical trial offering at Lake Region Healthcare Cancer Care and Research Center, please contact our Clinical Research Nurse at 218.736.8636.

S1207

SWOG 1207: Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
Specialty: Cancer, Oncology & Hematology
Description: This randomized phase III trial studies how well giving hormone therapy together with or without everolimus work in treating patients with breast cancer. clinicaltrials.gov/ct2/show/NCT01674140?term=swog+1207&rank=1
More Information: For more information on this clinic trial offering at Lake Region Healthcare Cancer Care & Research Center, please contact our Clinical Research Nurse at 218.736.8636.

A011203

Alliance A011203: A Randomized Phase II Trial of Tamoxifen versus Z-Endoxifen HCL in Postmenopausal Women with Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer.
Specialty: Cancer, Oncology, & Hematology
Description: This randomized phase II trial studies how well tamoxifen citrate works compared with z-endoxifen hydrochloride in treating patients with breast cancer that has spread to nearby tissue or lymph nodes or other parts of the body and has estrogen receptors but not human epidermal growth factor receptor 2 (HER2) receptors on the surface of its cells. Estrogen can cause the growth of tumor cells. Hormone therapy using tamoxifen citrate or z-endoxifen hydrochloride may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known whether tamoxifen citrate or z-endoxifen hydrochloride is more effective in treating patients with breast cancer.
clinicaltrials.gov/ct2/show/NCT02311933?term=A011203&rank=1
More Information: For more information on this clinical trial offering at Lake Region Healthcare Cancer Care & Research Center, please contact our Clinical Research Nurse at 218.736.8636.

BR003

NRG BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Specialty: Cancer, Oncology, & Hematology
Description: This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether doxorubicin hydrochloride and cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and carboplatin in treating triple-negative breast cancer.
clinicaltrials.gov/ct2/show/study/NCT02488967?term=BR003&rank=1
More Information: For more information on this clinical trial offering at Lake Region Healthcare Cancer Care & Research Center, please contact our Clinical Research Nurse at 218.736.8636.

Cancer Control

S0820

S0820 A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase II Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
Specialty: Cancer, Oncology & Hematology  
Description: The objective is to assess whether eflornithine 500 mg or sulindac 150 mg are effective in reducing the 3-year event rate of high risk adenoma or second primary colorectal cancer in Stage 0, I II and III colon cancer patients. clinicaltrials.gov/ct2/show/NCT00874211
More Information: For more information on this clinic trial offering at Lake Region Healthcare Cancer Care & Research Center, please contact our Clinical Research Nurse at 218.736.8636.

EAY131

NCI-MATCH EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Specialty: Cancer, Oncology, & Hematology
Description: This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors or lymphomas.
clinicaltrials.gov/ct2/show/NCT02465060?term=EAY131&rank=1
More Information: For more information on this clinical trial offering at Lake Region Healthcare Cancer Care & Research Center, please contact our Clinical Research Nurse at 218.736.8636.

Genitourinary

S1216

SWOG 1216: Phase III Androgen Deprivation Therapy+TAK-700 vs. Androgen Deprivation Therapy +Bicalutamide for Metastatic Prostate Cancer
Specialty: Cancer, Oncology & Hematology
Description: The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.  clinicaltrials.gov/ct2/show/NCT01809691?term=s1216&rank=1
More Information: For more information on this clinic trial offering at Lake Region Healthcare Cancer Care & Research Center, please contact our Clinical Research Nurse at 218.736.8636.

S1314

SWOG S1314: A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Specialty: Cancer, Oncology & Hematology
Description: The primary focus of this study is to see if looking at tumor biomarkers using a program called coexpression extrapolation or "COXEN" may predict a patient's response to chemotherapy before surgery. https://clinicaltrials.gov/ct2/show/NCT02177695?term=s1314&rank=1
More Information: For more information on this clinical trial offering at Lake Region Healthcare Cancer Care & Research Center, please contact our clinical research nurse at 218.736.8636.

Lung

S1400

SWOG S1400: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer.
Specialty: Cancer, Oncology & Hematology
Description: This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study "Master Protocol". The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes a "non-match" sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies. This sub-study will compare a non-match therapy to standard of care also with the goal of approval.
More Information: For more information on this clinic trial offering at Lake Region Healthcare Cancer Care & Research Center, please contact our Clinical Research Nurse at 218.736.8636.

A151216

Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Specialty: Cancer, Oncology, & Hematology
Description: This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes. clinicaltrials.gov/ct2/show/NCT02194738?term=A151216&rank=1
More Information: For more information on this clinical trial offering at Lake Region Healthcare Cancer Care & Research Center, please contact our Clinical Research Nurse at 218.736.8636.

Melanoma

S1404

National Cancer Institute S1404: High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
Specialty: Cancer, Oncology & Hematology
Description: This randomized phase III trial studies how well high-dose recombinant interferon alfa-2B or ipilimumab works compared with pembrolizumab in treating patients with stage III-IV melanoma that has been removed by surgery but is likely to come back or spread. High-dose recombinant interferon alfa-2B may help shrink or slow the growth of melanoma. Monoclonal antibodies, such as ipilimumab and pembrolizumab, may block tumor growth in different ways by targeting certain cells. It is not yet known whether high-dose recombinant interferon alfa-2B or ipilimumab is more effective than pembrolizumab in treating patients with melanoma. https://clinicaltrials.gov/ct2/show/NCT02506153?term=S1404&rank=1
More Information: For more information on this clinical trial offering at Lake Region Healthcare Caner Care & Research Center, please contact our Clinical Research Nurse at 218.736.8636.

Multiple Myeloma

E3A06

ECOG E3A06: Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Specialty: Cancer, Oncology & Hematology
Description: This phase II/III trial is studying lenalidomide to see how well it works compared to observation in treating patients with asymptomatic high-risk smoldering multiple myeloma. Biological therapies such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Sometimes the cancer may not need treatment until it progresses. In this case, observation may be sufficient. clinicaltrials.gov/ct2/show/NCT01169337
More Information: For more information on this clinic trial offering at Lake Region Healthcare Cancer Care & Research Center, please contact our Clinical Research Nurse at 218.736.8636.

S1211

SWOG S1211: A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
Specialty: Cancer, Oncology, & Hematology
Description: Lenalidomide and bortezomib may stop the growth of multiple myeloma by blocking blood flow to the tumor. Also, bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as elotuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as lenalidomide and dexamethasone also work in different ways to kill tumor cells or stop them from growing. Giving elotuzumab together with chemotherapy may be a better way to block cancer growth. This phase I/II trial is studying the side effects and best dose of elotuzumab and to see how well it works when given with lenalidomide, bortezomib, and dexamethasone in treating patients with multiple myeloma. clinicaltrials.gov/ct2/show/NCT01668719?term=S1211&rank=1
More Information: For more information on this clinical trial offering at Lake Region Healthcare Cancer Care & Research Center, please contact our Clinical Research Nurse at 218.736.8636.

Clinical Trials Resources

Back to top